Paediatric Diseases Working Party (PDWP)
Type d'étude:
Numéro de l'étude:
8417025
Type de traitement à base de cellules souches:
Maladies:
Titre court:
Objectif principal:
The primary endpoints are: Platelet count on day +30 and +90 after treatment initiation and +30 after treatment discontinuation
Secondary endpoints are: Reduction of platelet transfusions, Possible adverse events, Relapse of primary condition, Status 1 year post HSCT.
Secondary endpoints are: Reduction of platelet transfusions, Possible adverse events, Relapse of primary condition, Status 1 year post HSCT.
Principaux critères d'inclusion:
- Any patient who received Romiplostim or Eltrombopag post HSCT for thrombocytopenia
- Age at HSCT < 18 years
- Diagnosis after 2013
- Allogeneic and/or autologous stem cell transplantation
- Age at HSCT < 18 years
- Diagnosis after 2013
- Allogeneic and/or autologous stem cell transplantation
Pays:
Investigateur principal:
Asaf David Yanir
Coordinateur EBMT de l'étude:
Arnaud Dalissier
E-mail du coordinateur de l'étude:
arnaud.dalissier@upmc.fr